# US 2010/0145042 A1 · Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0145042 A1
- Document ID: US20100145042A1
- Status: Published application
- Kind: A1
- Application number: 12/706,279
- Filed: 2010-02-16
- Published: 2010-06-10
- Earliest claimed: 2006-09-22
- Assignees: Solvay Pharmaceuticals GmbH
- Inventors: Arnold Van Loevezijn; Wouter I. Iwema Bakker; Hiskias G. Keizer; Jan Zorgdrager; Martina A.W. Van Der Neut; Cornelis G. Kruse
- Web page: https://patentgrep.com/patent/US20100145042A1

## CPC

- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/12: Antidiarrhoeals
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 231/06: having one double bond between ring members or between a ring member and a non-ring member
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/54: condensed with carbocyclic rings or ring systems
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07D 491/10: Spiro-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention concerns compounds of the general formula (1): and derivatives thereof, which are antagonists of 5-HT6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes.

## Claims

### Claim at position 1

1-27. (canceled)

### Claim 28

A compound of formula (1X):
or a stereoisomer, N-oxide thereof, or pharmacologically acceptable salt of any of the foregoing, wherein:
X is chosen from halogen and S-alkyl(C1-4);
R1 is chosen from hydrogen, an unsubstituted alkyl(C1-4) group, and an alkyl(C1-4) group substituted with one or more halogen atoms;
R2 and R3 independently are chosen from hydrogen, an unsubstituted alkyl(C1-4) group, an alkyl-(C1-4) group substituted with one or more halogen atoms, and a phenyl-alkoxy(C1-4)-alkyl(C1-4) group optionally substituted with one or more halogen atoms, or,
R1 and R2, together with the carbon atoms marked ‘a’ and ‘b’ form a C5-8-cycloalkyl ring, or
R2 and R3, together with the carbon atom marked ‘b’ form a C3-8-cycloalkyl ring, or,
R2 and R3, together with the carbon atom marked ‘b’ form an C5-8-heterocycloalkyl ring optionally substituted with one or more substituents Y, wherein Y is chosen from (C1-3)alkyl, tri-fluoromethyl, fluoro, chloro, bromo, hydroxyl, (C1-3)alkyloxy, trifluoromethoxy, and amino;
R4 and R5 independently are chosen from hydrogen, an unsubstituted alkyl(C1-4) group, an alkyl-(C1-4) group substituted with one or more halogen atoms, a monocyclic or a fused-bicyclic aromatic or hetero-aromatic group, optionally substituted with one or more substituents Y, as defined above, or,
R3 and R4, together with the carbon atoms marked ‘b’ and ‘c’ form a C3-8-cycloalkyl ring, or,
R3 and R4, together with the carbon atoms marked ‘b’ and ‘c’ form a C5-8-heterocycloalkyl ring, optionally substituted with one or more substituents Y, as defined above; and
R8 is a monocyclic or a fused-bicyclic aromatic or hetero-aromatic group, optionally substituted with one or more substituents Y, as defined above, or,
R8 is a —CR9═CR10-aryl group wherein R9 and R10 independently are chosen from hydrogen and an alkyl-(C1-3) group, and wherein aryl is chosen from a monocyclic, a fused bicyclic aromatic, and a hetero-aromatic group, or,
R8 is chosen from a —C≡C-aryl group, wherein aryl is chosen from a monocyclic, a fused bicyclic aromatic, and a hetero-aromatic group, a piperidinyl group optionally substituted with one or more substituents Y, as defined above, and a —NR11R12 group, wherein R11 and R12 independently are chosen from hydrogen, an unsubstituted alkyl-(C1-3) group, and a phenyl or benzyl group, wherein the phenyl or benzyl group is optionally substituted with one or more substituents Y, as defined above.

### Claim 29

A compound of formula (1Z):
or a stereoisomer, N-oxide thereof, or pharmacologically acceptable salt of any of the foregoing, wherein:
R1 is chosen from hydrogen, an unsubstituted alkyl(C1-4) group, and an alkyl(C1-4) group substituted with one or more halogen atoms;
R2 and R3 independently are chosen from hydrogen, an unsubstituted alkyl(C1-4) group, an alkyl-(C1-4) group substituted with one or more halogen atoms, and a phenyl-alkoxy(C1-4-alkyl(C1-4) group optionally substituted with one or more halogen atoms, or,
R1 and R2, together with the carbon atoms marked ‘a’ and ‘b’ form a C5-8-cycloalkyl ring, or
R2 and R3, together with the carbon atom marked ‘b’ form a C3-8-cycloalkyl ring, or,
R2 and R3, together with the carbon atom marked ‘b’ form an C5-8-heterocycloalkyl ring optionally substituted with one or more substituents Y, wherein Y is chosen from (C1-3)alkyl, tri-fluoromethyl, fluoro, chloro, bromo, hydroxyl, (C1-3)alkyloxy, trifluoromethoxy, and amino;
R4 and R5 independently are chosen from hydrogen, an unsubstituted alkyl(C1-4) group, an alkyl-(C1-4) group substituted with one or more halogen atoms, a monocyclic or a fused-bicyclic aromatic or hetero-aromatic group, optionally substituted with one or more substituents Y, as defined above, or,
R3 and R4, together with the carbon atoms marked ‘b’ and ‘c’ form a C3-8-cycloalkyl ring, or,
R3 and R4, together with the carbon atoms marked ‘b’ and ‘c’ form a C5-8-heterocycloalkyl ring, optionally substituted with one or more substituents Y, as defined above; and
R6 and R7 independently are chosen from a hydrogen atom, an alkyl(C1-4) group, an alkyl(C1-4) group substituted with one or more halogen atoms, a (C1-3)alkoxy group, a dialkyl(C1-3)-amino-alkyl(C1-3) group, a monocyclic or fused bicyclic aromatic or hetero-aromatic group, optionally substituted with one or more substitutents Y, as defined above, a C5-8-cycloalkyl or a C5-8-heterocycloalkyl group, optionally substituted with one or more substituents Y, as defined above, and a benzyl group, or
R6 and R7, together with the nitrogen atom to which they are attached, form a C5-8-hetero-cycloalkyl group, optionally substituted with one or more substituents Y, as defined above.

### Claim 30

A process for preparing a compound of formula (1′), comprising:
(i) reacting a compound of formula (X), obtained by reacting a compound of formula (IX) with an alkyl halide, with a pyrazoline in the presence of a base, to yield a compound of formula (1Z), and
(ii) reacting a compound of formula (1Z) with a sulfonyl halide of formula R8—SO2—X, wherein X is Br, Cl or F, in an aprotic solvent, in the presence of a base,
wherein:
R1 is chosen from hydrogen, an unsubstituted alkyl(C1-4) group, and an alkyl(C1-4) group substituted with one or more halogen atoms;
R2 and R3 independently are chosen from hydrogen, an unsubstituted alkyl(C1-4) group, an alkyl-(C1-4 group substituted with one or more halogen atoms, and a phenyl-alkoxy(C1-4)-alkyl(C1-4) group optionally substituted with one or more halogen atoms, or,
R1 and R2, together with the carbon atoms marked ‘a’ and ‘b’ form a C5-8-cycloalkyl ring, or
R2 and R3, together with the carbon atom marked ‘b’ form a C3-8-cycloalkyl ring, or,
R2 and R3, together with the carbon atom marked ‘b’ form an C5-8-heterocycloalkyl ring optionally substituted with one or more substituents Y, wherein Y is chosen from (C1-3)alkyl, tri-fluoromethyl, fluoro, chloro, bromo, hydroxyl, (C1-3)alkyloxy, trifluoromethoxy, and amino;
R4 and R5 independently are chosen from hydrogen, an unsubstituted alkyl(C1-4) group, an alkyl-(C1-4) group substituted with one or more halogen atoms, a monocyclic or a fused-bicyclic aromatic or hetero-aromatic group, optionally substituted with one or more substituents Y, as defined above, or,
R3 and R4, together with the carbon atoms marked ‘b’ and ‘c’ form a C3-8-cycloalkyl ring, or,
R3 and R4, together with the carbon atoms marked ‘b’ and ‘c’ form a C5-8-heterocycloalkyl ring, optionally substituted with one or more substituents Y, as defined above;
R6 independently is chosen from a hydrogen atom, an alkyl(C1-4) group, an alkyl(C1-4) group substituted with one or more halogen atoms, a (C1-3)alkoxy group, a dialkyl(C1-3)-amino-alkyl(C1-3) group, a monocyclic or fused bicyclic aromatic or hetero-aromatic group, optionally substituted with one or more substitutents Y, as defined above, a C5-8-cycloalkyl or a C5-8-heterocycloalkyl group, optionally substituted with one or more substituents Y, as defined above, and a benzyl group; and
R8 is a monocyclic or a fused-bicyclic aromatic or hetero-aromatic group, optionally substituted with one or more substituents Y, as defined above, or,
R8 is a —CR9═CR10-aryl group wherein R9 and R10 independently are chosen from hydrogen and an alkyl-(C1-3) group, and wherein aryl is chosen from a monocyclic, a fused bicyclic aromatic, and a hetero-aromatic group, or,
R8 is chosen from a —C≡C-aryl group, wherein aryl is chosen from a monocyclic, a fused bicyclic aromatic, and a hetero-aromatic group, a piperidinyl group optionally substituted with one or more substituents Y, as defined above, and a —NR11R12 group, wherein R11 and R12 independently are chosen from hydrogen, an unsubstituted alkyl-(C1-3) group, and a phenyl or benzyl group, wherein the phenyl or benzyl group is optionally substituted with one or more substituents Y, as defined above.
